keyword
MENU ▼
Read by QxMD icon Read
search

metformin users

keyword
https://www.readbyqxmd.com/read/27936468/rosiglitazone-reduces-breast-cancer-risk-in-taiwanese-female-patients-with-type-2-diabetes-mellitus
#1
Chin-Hsiao Tseng
This study investigated whether rosiglitazone may affect breast cancer risk in female patients with type 2 diabetes mellitus in Taiwan. The reimbursement database of all female patients with type 2 diabetes mellitus under oral antidiabetic agents or insulin from 1996 to 2009 was retrieved from the National Health Insurance. An entry date was set on 1 January 2006 and a total of 431447 patients were followed up for breast cancer incidence till the end of 2009. Incidences for ever users, never users and subgroups of rosiglitazone dose-response parameters (tertile cutoffs of cumulative duration and cumulative dose) were calculated and hazard ratios estimated by Cox regression...
December 8, 2016: Oncotarget
https://www.readbyqxmd.com/read/27926481/metformin-therapy-and-risk-of-colorectal-adenomas-and-colorectal-cancer-in-type-2-diabetes-mellitus-patients-a-systematic-review-and-meta-analysis
#2
REVIEW
Feifei Liu, Lijing Yan, Zhan Wang, Yuanan Lu, Yuanyuan Chu, Xiangyu Li, Yisi Liu, Dongsheng Rui, Shaofa Nie, Hao Xiang
Recent evidence indicates that metformin therapy may be associated with a decreased colorectal adenoma/colorectal cancer risk in type 2 diabetes patients. However, results are not consistent. We therefore performed a systematic review and meta-analysis to assess the association between metformin therapy and risk of colorectal adenomas/colorectal cancer in type 2 diabetes mellitus patients. We searched the literature published before Aug 31, 2016 in four databases: PubMed, Embase database, CNKI and VIP Library of Chinese Journal...
December 1, 2016: Oncotarget
https://www.readbyqxmd.com/read/27908558/time-varying-risk-for-breast-cancer-following-initiation-of-glucose-lowering-therapy-in-women-with-type-2-diabetes-exploring-detection-bias
#3
Samantha L Bowker, Mu Lin, Dean T Eurich, Jeffrey A Johnson
OBJECTIVES: To explore detection bias in the association between glucose-lowering therapies and breast cancer in a cohort of women with type 2 diabetes. METHODS: This was a retrospective, population-based cohort study. We identified new users of metformin, sulfonylureas, thiazolidinediones and insulin during the index period of January 1, 2003, to December 31, 2010. The main outcome was incident breast cancer, and patients were followed up from drug exposure index date until death, diagnosis of another type of cancer, termination of medical insurance or December 31, 2010...
November 29, 2016: Canadian Journal of Diabetes
https://www.readbyqxmd.com/read/27881709/relationship-between-metformin-use-and-recurrence-and-survival-in-patients-with-resected-stage-iii-colon-cancer-receiving-adjuvant-chemotherapy-results-from-north-central-cancer-treatment-group-n0147-alliance
#4
Preet Paul Singh, Qian Shi, Nathan R Foster, Axel Grothey, Suresh G Nair, Emily Chan, Anthony F Shields, Richard M Goldberg, Sharlene Gill, Morton S Kahlenberg, Frank A Sinicrope, Daniel J Sargent, Steven R Alberts
BACKGROUND: Preclinical and epidemiological data suggest that metformin might have antineoplastic properties against colon cancer (CC). However, the effect of metformin use on patient survival in stage III CC after curative resection is unknown. The survival outcomes were comparable regardless of the duration of metformin use. PATIENTS AND METHODS: Before randomization to FOLFOX (folinic acid, 5-fluorouracil, oxaliplatin) with or without cetuximab, 1,958 patients with stage III CC enrolled in the N0147 study completed a questionnaire with information on diabetes mellitus (DM) and metformin use...
November 23, 2016: Oncologist
https://www.readbyqxmd.com/read/27879196/treatment-persistence-in-the-use-of-basal-insulins-in-poland-and-germany%C3%A2
#5
Wolfgang Rathmann, Marcin Czech, Edward Franek, Karel Kostev
AIMS: To compare short-term basal insulin therapy persistence and its predictors in Poland and Germany. METHODS: Persistence was defined as proportions of patients remaining on the initial basal insulin (analogs: Poland: n = 6,889, Germany: n = 454,067; neutral protamine Hagedorn (NPH) insulins: Poland: n = 50,761, Germany: n = 226,064) over 2 years based on nationwide prescription databases (LRx; IMS Health) in Poland and Germany from 2013 to 2015. Persistence was evaluated by Kaplan-Meier curves (log-rank tests)...
November 23, 2016: International Journal of Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/27865756/association-of-insulin-dosage-with-mortality-or-major-adverse-cardiovascular-events-a-retrospective-cohort-study
#6
John-Michael Gamble, Eugene Chibrikov, Laurie K Twells, William K Midodzi, Stephanie W Young, Don MacDonald, Sumit R Majumdar
BACKGROUND: Existing studies have shown conflicting evidence regarding the safety of exogenous insulin therapy in patients with type 2 diabetes. In particular, observational studies have reported an increased risk of death and cardiovascular disease among users of higher versus lower doses of insulin. We aimed to quantify the association between increasing dosage of insulin exposure and death and cardiovascular events, while taking into account time-dependent confounding and mediation that might have biased previous studies...
November 16, 2016: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/27861855/effect-of-statin-on-hepatocellular-carcinoma-in-patients-with-type-2-diabetes-a-nationwide-nested-case-control-study
#7
Gyuri Kim, Suk-Yong Jang, Eugene Han, Yong-Ho Lee, Se-Young Park, Chung Mo Nam, Eun Seok Kang
Relationship on new statin use and the risk of hepatocellular carcinoma (HCC) in patients with incident type 2 diabetes mellitus (T2DM), who might be at the risk of developing HCC, is uncertained. A nationwide population-based nested case-control study was conducted within the National Health Insurance Service National Sample Cohort 2002-2013 in Korea. Newly prescribed statin after newly diagnosed T2DM was defined as statin use. Controls were matched to case patients on age, sex, follow-up time, and the date of diabetes diagnosis at a five-to-one ratio...
November 7, 2016: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/27861146/metformin-and-esophageal-cancer-risk-in-taiwanese-patients-with-type-2-diabetes-mellitus
#8
Chin-Hsiao Tseng
This study evaluated whether metformin might reduce esophageal cancer risk. Patients with type 2 diabetes mellitus diagnosed during 1999-2005 were recruited from the reimbursement database of Taiwan's National Health Insurance. Those newly treated with metformin (n = 288013, "ever users of metformin") or other antidiabetic drugs (n = 16216, "never users of metformin") were followed until December 31, 2011. Sensitivity analyses were conducted in a matched-pair sample of 16216 never users and 16216 ever users...
November 16, 2016: Oncotarget
https://www.readbyqxmd.com/read/27792125/impact-of-metformin-use-on-lactate-kinetics-in-patients-with-severe-sepsis-and-septic-shock
#9
Joongmin Park, Sung Yeon Hwang, Ik Joon Jo, Kyeongman Jeon, Gee Young Suh, Tae Rim Lee, Hee Yoon, Won Chul Cha, Min Seob Sim, K C Carriere, Seungmin Yeon, Tae Gun Shin
BACKGROUND: We aimed to evaluate the impact of metformin use on lactate kinetics in patients with severe sepsis and septic shock. METHODS: We analyzed data from a registry that included patients who presented to the emergency department and met criteria for severe sepsis or septic shock. Patients were divided into two groups based on metformin use. We compared lactate concentrations, lactate clearance (LC), and normalization at 6 hours (H6) and 24 hours (H24) after the initial (H0) measurement...
October 27, 2016: Shock
https://www.readbyqxmd.com/read/27789974/nationwide-trends-in-glucose-lowering-drug-use-denmark-1999-2014
#10
Diana Hedevang Christensen, Jørgen Rungby, Reimar Wernich Thomsen
PURPOSE: The objective of this study was to examine nationwide population-based time trends in the utilization of all glucose-lowering drugs in Denmark from 1999 to 2014. METHODS: Based on nationwide data from the Register of Medicinal Products Statistics, we retrieved sales statistics on glucose-lowering drugs and reported the total number of users and the prevalence of users per 1,000 inhabitants in 1-year intervals for all glucose-lowering drug classes. RESULTS: The annual prevalence of glucose-lowering drug users increased more than twofold from 19 per 1,000 inhabitants in 1999 (n=98,362) to 41 per 1,000 in 2014 (n=233,230)...
2016: Clinical Epidemiology
https://www.readbyqxmd.com/read/27775209/metformin-confers-risk-reduction-for-developing-hepatocellular-carcinoma-recurrence-after-liver-resection
#11
Kun-Ming Chan, Chang-Fu Kuo, Jun-Te Hsu, Meng-Jiun Chiou, Yu-Chao Wang, Tsung-Han Wu, Chen-Fang Lee, Ting-Jung Wu, Hong-Shiue Chou, Wei-Chen Lee
BACKGROUND: Hepatocellular carcinoma recurrence following liver resection remains a great concern. The study aims to examine the chemopreventive effect of metformin in patients undergoing liver resection for hepatocellular carcinoma from a population-based study. METHODS: All patients registered as having hepatocellular carcinoma between January 1995 and December 2011 in a nationwide database were retrospectively analysed. Outcomes related to liver resection and the presence of diabetes mellitus were assessed...
October 24, 2016: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/27730072/study-of-vitamin-b12-deficiency-and-peripheral-neuropathy-in-metformin-treated-early-type-2-diabetes-mellitus
#12
Rudra Prasad Roy, Kaushik Ghosh, Manas Ghosh, Amitava Acharyya, Ambarish Bhattacharya, Mrinal Pal, Sisir Chakraborty, Nilanjan Sengupta
BACKGROUND: Long-term therapy with metformin was shown to decrease the Vitamin B12 level and manifested as peripheral neuropathy. AIM: The aim of this study is to define the prevalence of Vitamin B12 deficiency in early Type 2 diabetic patients (duration ≤5 years or drug treatment ≤3 years) and the relationship among metformin exposure and levels of cobalamin (Cbl), folic acid, and homocysteine (Hcy) with severity of peripheral neuropathy. METHODOLOGY: This is a cross-sectional study involving randomly selected ninety patients (male 56, female 34) between age groups of 35 and 70 years, comparing those who had received >6 months of metformin (Group A) (n = 35) with those without metformin (Group B) (n = 35) and patients taking metformin with other oral hypoglycemic agent (Group C) (n = 20)...
September 2016: Indian Journal of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/27728103/-rediscovering-arneth-count-prevalence-of-megaloblastic-anemia-in-chronic-metformin-users
#13
Deenadayalan T, R Jayanthi
No abstract text is available yet for this article.
January 2016: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/27688104/diabetes-mellitus-metformin-and-head-and-neck-cancer
#14
Rejane Augusta de Oliveira Figueiredo, Elisabete Weiderpass, Eloiza Helena Tajara, Peter Ström, André Lopes Carvalho, Marcos Brasilino de Carvalho, Jossi Ledo Kanda, Raquel Ajub Moyses, Victor Wünsch-Filho
INTRODUCTION: Diabetes mellitus (DM (Diabetes Mellitus)) is directly associated with some cancers. However, studies on the association between diabetes mellitus and head and neck cancer (HNC (Head and Neck Cancer)) have rendered controversial results. The objective of this study was to evaluate the association between DM and HNC, as well as the impact of metformin use on the risk of HNC. MATERIAL AND METHODS: This case-control study was conducted within the framework of the Brazilian Head and Neck Genome Project in 2011-2014...
October 2016: Oral Oncology
https://www.readbyqxmd.com/read/27687012/impact-of-chromium-dinicocysteinate-supplementation-on-inflammation-oxidative-stress-and-insulin-resistance-in-type-2-diabetic-subjects-an-exploratory-analysis-of-a-randomized-double-blind-placebo-controlled-study
#15
Zainulabedin M Saiyed, James P Lugo
BACKGROUND: Chromium dinicocysteinate (CDNC) is a unique chromium complex consisting of chromium, niacin, and L-cysteine. Previous preclinical and clinical studies support the safety and efficacy of CDNC in modulating oxidative stress, vascular inflammation, and glycemia in type 2 diabetes. OBJECTIVE: Herein, we report the results of several exploratory analyses conducted on type 2 diabetic subjects who previously participated in a 3-month randomized, double-blind, placebo-controlled trial and were treated with only metformin as standard diabetic care in addition to receiving the test supplementations...
2016: Food & Nutrition Research
https://www.readbyqxmd.com/read/27681864/metformin-as-an-adjuvant-treatment-for-cancer-a-systematic-review-and-meta-analysis
#16
C Coyle, F H Cafferty, C Vale, R E Langley
BACKGROUND: Metformin use has been associated with a reduced risk of developing cancer and an improvement in overall cancer survival rates in meta-analyses, but, to date, evidence to support the use of metformin as an adjuvant therapy in individual cancer types has not been presented. PATIENTS AND METHODS: We systematically searched research databases, conference abstracts and trial registries for any studies reporting cancer outcomes for individual tumour types in metformin users compared with non-users, and extracted data on patients with early-stage cancer...
September 28, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27642297/myoinositol-as-a-safe-and-alternative-approach-in-the-treatment-of-infertile-pcos-women-a-german-observational-study
#17
Pedro-Antonio Regidor, Adolf Eduard Schindler
The use of 2 × 2000 mg myoinositol + 2 × 200 μg folic acid per day is a safe and promising tool in the effective improvement of symptoms and infertility for patients with a polycystic ovary syndrome (PCOS). Using a questionnaire an observational study was performed under German gynecologists to collect data on ovulation and pregnancy rates in PCOS patients with infertility. In this observational study, 3602 infertile women used myoinositol and folic acid between 2 and 3 months in a dosage of 2 × 2000 mg myoinositol + 2 × 200 μg folic acid per day...
2016: International Journal of Endocrinology
https://www.readbyqxmd.com/read/27642000/patterns-of-anti-diabetic-medication-use-in-patients-with-type-2-diabetes-mellitus-in-england-and-wales
#18
Preeti Datta-Nemdharry, Andrew Thomson, Julie Beynon, Katherine Donegan
PURPOSE: The purpose of this study is to characterise how Type 2 Diabetes Mellitus (T2DM) is treated in England and Wales and whether this adheres to 2009 National Institute for Health and Care Excellence (NICE) guidance on management of T2DM. METHODS: Data for T2DM patients aged 18+ years prescribed at least one anti-diabetic drug between 01/01/2000-30/06/2012 were extracted from the Clinical Practice Research Datalink. We examined the sequences in which anti-diabetic drugs were prescribed and, for patients on the most common anti-diabetic drug pathways, evaluated average HbA1c values at treatment initiation and at progression to a second or third-line anti-diabetic drug class, including insulin...
September 19, 2016: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/27640062/insulin-monotherapy-compared-with-the-addition-of-oral-glucose-lowering-agents-to-insulin-for-people-with-type-2-diabetes-already-on-insulin-therapy-and-inadequate-glycaemic-control
#19
REVIEW
Rimke C Vos, Mariëlle Jp van Avendonk, Hanneke Jansen, Alexander N Goudswaard, Maureen van den Donk, Kees Gorter, Anneloes Kerssen, Guy Ehm Rutten
BACKGROUND: It is unclear whether people with type 2 diabetes mellitus on insulin monotherapy who do not achieve adequate glycaemic control should continue insulin as monotherapy or can benefit from adding oral glucose-lowering agents to the insulin therapy. OBJECTIVES: To assess the effects of insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin monotherapy for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control...
September 18, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27639123/genetic-variations-in-tcf7l2-influence-therapeutic-response-to-sulfonylureas-in-indian-diabetics
#20
Dipali Dhawan, Harish Padh
Sulfonylureas are widely used to treat type 2 diabetes, with considerable inter-individual variation in the hypoglycaemic response to sulfonylureas. Genetic variants in the gene encoding for transcription factor-7-like 2 (TCF7L2) have been associated with type 2 diabetes. This study aimed to study the effect of variations in TCF7L2 on therapeutic response to sulfonylureas in Type 2 diabetes mellitus patients. The effect of TCF7L2 rs12255372, rs7903146 and rs4506565 genotypes on glycaemic response was observed in 250 diabetic patients treated with sulfonylureas and sulfonylureas along with metformin...
September 8, 2016: Diabetes Research and Clinical Practice
keyword
keyword
90703
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"